Agomab Therapeutics NV Adrs (AGMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 12-2025 | 09-2025 | 12-2024 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -36,010 | -70,766 | -52,771 | -50,066 |
| Depreciation Amortization | 201 | 248 | 353 | 337 |
| Accounts payable and accrued liabilities | 1,832 | N/A | N/A | N/A |
| Other Working Capital | 566 | 459 | -1,127 | -1,387 |
| Other Operating Activity | -1,374 | 11,519 | 8,461 | 443 |
| Operating Cash Flow | $-34,785 | $-58,540 | $-45,084 | $-50,673 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | N/A | -5 | N/A | -730 |
| Other Investing Activity | 0 | -37,337 | -3,507 | 0 |
| Investing Cash Flow | $N/A | $-37,341 | $-3,507 | $-730 |
| Cash Flows From Financing Activities | ||||
| Common Stock Issued | 190,640 | N/A | N/A | N/A |
| Other Financing Activity | 1,307 | -382 | -355 | 104,706 |
| Financing Cash Flow | $191,947 | $-382 | $-355 | $104,706 |
| Exchange Rate Effect | N/A | 51 | N/A | -221 |
| Beginning Cash Position | 100,478 | 193,989 | 200,418 | 132,451 |
| End Cash Position | 257,640 | 97,773 | 151,472 | 185,536 |
| Net Cash Flow | $157,162 | $-96,215 | $-48,947 | $53,085 |
| Free Cash Flow | ||||
| Operating Cash Flow | -34,785 | -58,540 | -45,084 | -50,673 |
| Free Cash Flow | -34,785 | -58,540 | -45,084 | -50,673 |